Inhalation API manufacturer Inke has announced a €9 million expansion of its manufacturing facility in Castellbisbal, Barcelona, Spain “to reinforce focus on inhalation micronized APIs,” with the aim of tripling its production capacity by 2024. According to Inke, the site currently makes 34 APIs for pharma companies in the US, Europe, Turkey, Japan, China, and Korea, including 12 APIs for inhalation. The company, a subsidiary of Neuraxpharm, said that it expects to spend the majority of the €9 million in 2022.
Neuraxpharm CEO Jörg Thomas Dierks commented, “Inke is a key supplier to major generic and branded companies in over 40 countries due to its very strong and entrenched competitive position. The segment of micronized inhalation APIs is highly attractive and poised for future growth, and I am convinced that this investment contributes significantly to extending our leading position in this market.”
Inke General Manager Miquel Bachs said, “We expect the increased global demand for respiratory APIs will allow us to grow our business considerably and to further strengthen our market position as a leading global API supplier specialized in inhalation therapies. I am proud that with this investment, Inke’s production site in the province of Barcelona is made future-proof.”
Read the Inke press release.
